uniQure’s Post

In this cohort study with up to 5 years of follow-up, dupilumab maintained its clinical effectiveness, while two-thirds of patients tapered to a dosing interval of every 3 or 4 weeks. https://ja.ma/3yCtPRu

The latest supplement to JCAD reviews response data from the over 2,000 biologic-experienced patients included in the UCB bimekizumab #psoriasis clinical trials and discusses how this data can inform real-world practice and patient counseling. Click here to read: https://ow.ly/agZL50RAygy Many thanks to Omar Noor, MD, FAAD, and Jacob Beer, MD for providing their review and commentary.

EASTBOURNE is one of the largest prospective clinical registry that investigated the safety and efficacy of Magic Touch Sirolimus DCB on 2123 consecutive patients in broad range of complex coronary disease cohorts , including Bifurcation Lesions. EASTBOURNE - BIF is a substudy addressing bifurcation lesions, which are associated with less favorable outcomes compared to other lesions. The results showed the use of Magic Touch Sirolimus DCB alone or in combination with DES represented a safe and effective alternative to Stents for treatment of Bifurcation. Magic Touch is the Worlds 1st CE Certified, US FDA breakthrough designated Drug coated balloon with the largest and longest studied clinical program touching over 23K patients worldwide with results that are altering standards of care and shaping the future of percutaneous therapy. # Game Changer Technology # US FDA breakthrough Designated # Over 180 K patients treated WorldWide - confidence Inspired by Real World Use.

EASTBOURNE is one of the largest prospective clinical registry that investigated the safety and efficacy of Magic Touch Sirolimus DCB on 2123 consecutive patients in broad range of complex coronary disease cohorts , including Bifurcation Lesions. EASTBOURNE - BIF is a substudy addressing bifurcation lesions, which are associated with less favorable outcomes compared to other lesions. The results showed the use of Magic Touch Sirolimus DCB alone or in combination with DES represented a safe and effective alternative to Stents for treatment of Bifurcation. Magic Touch is the Worlds 1st CE Certified, US FDA breakthrough designated Drug coated balloon with the largest and longest studies clinical program touching over 23K patients worldwide with results that are altering standards of care and shaping the future of percutaneous therapy. # Game Changer Technology # US FDA breakthrough Designated # Over 180 K patients treated worldwide - confidence inspired by real world use.

⭐ New #PulmonaryFibrosis Clinical Trials ⭐ The PACT Network has newly endorsed pulmonary fibrosis clinical trials seeking participants.   Medicine and patient treatments would not have advanced as much as they have without the essential contribution of clinical trial participants.   For a full list of PACT endorsed trials and to find out what trial participation involves, visit the PACT Network Find a Trial webpage: https://lnkd.in/g9g2JySc   #PACTNetwork #PFClinicalTrials #IPFClinicalTrials #ILDClinicalTrials

Enrollments now open for this in depth clinical discussion covering the major aspects of eczema diagnosis and management and showcasing the new management tools to improve patients outcomes.

[STA®-Liatest® D-Di Plus to enhance VTE diagnostis and patient care] 💡 23% of samples with a positive Siemens result were negative when tested with Stago. This data highlights the potential of Stago D-Dimer Tests to reduce unnecessary investigations and improve clinical decisions for patients with suspected VTE (Venous ThromboEmbolism). A recent study from The New Zealand Medical Journal compared 2️⃣ D-dimer assays: INNOVANCE® DDimer (Siemens) and STA®-Liatest® D-Di Plus (Stago) 👉 https://lnkd.in/egrxWnNw 🔎 Stago assay also showed better resistance to antibody interference, ensuring more reliable and accurate results. By using STA®-Liatest® D-Di Plus, healthcare providers can enhance VTE diagnostis and patient care. 👉 https://lnkd.in/ep7ca73K #Diagnostics #Healthcare #VTE #DDimer #PatientCare DAVID COURTOIS Alex S. Aliénor Auby Tara Simpson, MBA Nichole Howard, MBA Paul Riley Clémence Chesne Hadison Yip Yannig QUEREL

Successfully bringing innovative precision medicines to market requires comprehensive clinical strategies that move these therapies from discovery to clinic. Importantly, it also entails deliberate inclusion of key stakeholders along the entire value chain, from suppliers through to patients. Dive deeper into the considerations for precision medicine in rare disease trials in our therapeutic spotlight: https://ow.ly/67Yn50TFljF

✨ **Phase IV** Clinical Trials: The Final Frontier of Patient Safety & Efficacy ✨ This week I’ve been reflecting on the essential role of *Phase IV Clinical Trials* in advancing patient care! 🚀 While earlier phases focus on proving efficacy, **Phase IV trials are vital for tracking long-term safety and effectiveness, especially in chronic diseases** where patients are treated for extended periods. With *heterogeneous patient populations*, Phase IV trials provide crucial data on how treatments work across diverse groups, identifying rare side effects and ensuring therapies are optimized for all. 🌍 I’m passionate about how *Phase IV* trials help optimize treatments for complex, chronic conditions while ensuring patient safety remains at the forefront. 💡 📊 Want to learn more? Follow my page for weekly updates! #ClinicalOperations #LeadershipDevelopment #ProjectManagement #ClinicalResearch #ClinicalTrials #DrugDevelopment #CRO #ClinicalResearchCareers

The Myeloma and AL Amyloidosis European Clinical Trial Navigator is a powerful online tool by Myeloma Patients Europe (MPE). This platform helps you find clinical trials for myeloma, MGUS, smouldering myeloma (SMM), and AL amyloidosis across Europe. For patients, the tool supports informed discussions with healthcare professionals on trial options and empowers advocates to push for better clinical trial access at national levels. Learn more in the link below https://lnkd.in/dDRHsv2Z #MyelomaAdvocacy #ClinicalTrials #MPE #MPENavigator #EuropeanMyelomaDay